160. Congenital ichthyosis Clinical trials / Disease details

Clinical trials : 42 / Drugs : 71 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 112

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04996485 (ClinicalTrials.gov)	March 1, 2021	21/7/2021	Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children	Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children	Congenital Ichthyosis	Drug: Secukinumab Injection;Drug: Ustekinumab Injection;Drug: Dupilumab Injection;Other: Symptomatic therapy	National Medical Research Center for Children's Health, Russian Federation	NULL	Recruiting	6 Months	18 Years	All	50	Phase 4	Russian Federation
2	NCT03041038 (ClinicalTrials.gov)	December 2016	17/1/2017	The Efficacy and Safety of Secukinumab in Patients With Ichthyoses	A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Maintenance Dosing Period to Evaluate the Efficacy and Safety of Secukinumab in Patients With Ichthyoses	Ichthyosis;Autosomal Recessive Congenital Ichthyosis;Lamellar Ichthyosis;Congenital Ichthyosiform Erythroderma;Epidermolytic Ichthyosis;Netherton Syndrome	Drug: Secukinumab;Drug: Placebo	Northwestern University	Icahn School of Medicine at Mount Sinai	Completed	18 Years	N/A	All	21	Phase 2	United States